- Home
- RPRX vs NLY Comparison
RPRX vs NLY Comparison
Compare RPRX & NLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- NLY
- Stock Information
- Founded
- RPRX 1996
- NLY 1996
- Country
- RPRX United States
- NLY United States
- Employees
- RPRX N/A
- NLY N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- NLY Real Estate Investment Trusts
- Sector
- RPRX Health Care
- NLY Real Estate
- Exchange
- RPRX Nasdaq
- NLY Nasdaq
- Market Cap
- RPRX 11.8B
- NLY 10.6B
- IPO Year
- RPRX 2020
- NLY 1997
- Fundamental
- Price
- RPRX $26.43
- NLY $19.81
- Analyst Decision
- RPRX Strong Buy
- NLY Strong Buy
- Analyst Count
- RPRX 6
- NLY 11
- Target Price
- RPRX $41.67
- NLY $21.40
- AVG Volume (30 Days)
- RPRX 3.1M
- NLY 6.1M
- Earning Date
- RPRX 11-06-2024
- NLY 10-23-2024
- Dividend Yield
- RPRX 3.18%
- NLY 13.13%
- EPS Growth
- RPRX 518.56
- NLY N/A
- EPS
- RPRX 2.55
- NLY N/A
- Revenue
- RPRX $2,266,003,000.00
- NLY $369,368,000.00
- Revenue This Year
- RPRX $12.38
- NLY N/A
- Revenue Next Year
- RPRX $11.26
- NLY $9.32
- P/E Ratio
- RPRX $10.35
- NLY N/A
- Revenue Growth
- RPRX N/A
- NLY N/A
- 52 Week Low
- RPRX $25.10
- NLY $17.23
- 52 Week High
- RPRX $31.66
- NLY $21.11
- Technical
- Relative Strength Index (RSI)
- RPRX 45.67
- NLY 54.11
- Support Level
- RPRX $25.47
- NLY $19.36
- Resistance Level
- RPRX $26.67
- NLY $19.89
- Average True Range (ATR)
- RPRX 0.64
- NLY 0.32
- MACD
- RPRX 0.05
- NLY 0.06
- Stochastic Oscillator
- RPRX 40.80
- NLY 84.22
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About NLY Annaly Capital Management Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The Company owns a portfolio of real estate related investments, including mortgage pass-through certificates, collateralized mortgage obligations, credit risk transfer securities, other securities representing interests in or obligations backed by pools of mortgage loans, residential mortgage loans and mortgage servicing rights. Its business objective is to generate net income for distribution to its stockholders and optimize its returns through prudent management of its diversified investment strategies. The Company's three investment groups are comprised of the following: Annaly Agency Group, Annaly Residential Credit Group, Annaly Mortgage Servicing Rights Group.